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Objectives: We sought to determine 5-year survival after extracorporeal membrane
oxygenation for cardiac failure and its predictors, to assess survival and its predic-
tors after bridging to transplantation or weaning from extracorporeal membrane
oxygenation, and to identify factors influencing the likelihood of these outcomes.
Methods: Two hundred two adults (mean age, 55 ± 14 years) were supported with
extracorporeal membrane oxygenation between 1992 and July 1999 after cardiac
failure. Follow-up extended to 7.5 years (mean, 3.8 ± 2 years). Multivariable haz-
ard function analysis identified predictors of survival, and logistic regression iden-
tified the determinants of bridging or weaning.
Results: Survival at 3 days, 30 days, and 5 years was 76%, 38%, and 24%, respective-
ly. Patients surviving 30 days had a 63% 5-year survival. Risk factors (P < .1) includ-
ed older age, reoperation, and thoracic aorta repair. Forty-eight patients were bridged
to transplantation, and 71 were weaned with intent for survival. Survival was similar
after either outcome (44% vs 40% 5-year survival, respectively). Failure to bridge or
wean included (P < .03) renal and hepatic failure on extracorporeal membrane oxy-
genator support, occurrence of a neurologic event, and absence of infection. The dom-
inant modes of death were cardiac failure and multisystem organ failure.
Conclusions: Extracorporeal membrane oxygenation is versatile and salvages some
patients who would otherwise die. Improvement in intermediate-term outcome will
require a multidisciplinary approach to protect organ function and limit organ injury
before and during this support.
Extracorporeal life support (extracorporeal membrane oxygena-tion [ECMO]) in newborns, infants, and children has beenwidely reported to have excellent results.1,2 ECMO in adults isless widely practiced and has met with less success. The focusof most reports has been on events during and shortly afterECMO. 
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Evolving from the experience with postcardiotomy cen-
trifugal pump support at The Cleveland Clinic Foundation,
ECMO has been used for circulatory support in a relatively
large number of adults. The purpose of this study was pri-
marily to determine intermediate-range (5-year) survival
and its pre-ECMO predictors. Secondarily, survival and its
predictors were assessed separately among patients bridged
from ECMO to transplantation or weaned from ECMO with
the intent of survival. To achieve the secondary purpose, we
also identified both pre-ECMO and ECMO factors that were
related to whether a patient was bridged to transplantation,
weaned from ECMO, or withdrawn from ECMO because of
futility.
Patients and Methods
Patients
Between 1992 and July 1, 1999, 202 patients were supported with
ECMO after cardiac failure. Patients with right ventricular failure
after insertion of an implantable left ventricular assist device
(LVAD) supported with ECMO as a right ventricular assist device
were not included in the analysis nor were patients supported by
venovenous ECMO for respiratory support. Patients supported
with ECMO ranged in age from 18 to 82 years (mean, 55 ± 14
years), and 145 (72%) were men. The general clinical characteris-
tics of these patients are presented in Appendix Tables A and B.
Of the 202 patients, 107 (53%) had undergone cardiotomy
(Appendix Table C). Among the patients receiving ECMO after
cardiotomy, 60 (56%) had undergone an isolated coronary artery
bypass grafting procedure, 19 (18%) had undergone coronary
artery bypass grafting and a valve operation, 15 (14%) had under-
gone a valve operation, 8 (7%) had undergone repair of congenital
heart disease, 4 (4%) had undergone aortic aneurysm repair, and 1
(1%) had undergone left ventriculectomy.
Conduct of ECMO
ECMO was initiated at the discretion of the operating or transplant
surgeon or interventional cardiologist, usually within 30 to 45 min-
utes of deciding to support the patient. For postcardiotomy
patients, failure to wean from bypass on inotropic agents and intra-
aortic balloon pump (IABP) support prompted ECMO insertion.
Absolute hemodynamic criteria were not used. For patients in
shock, ECMO was preferred over direct LVAD support because
many patients had prior cardiac operations, were near death, and
candidacy for transplantation had not been clarified.
Venoarterial ECMO was instituted by means of peripheral can-
nulation (common femoral artery and vein) in 153 (76%) patients
and central cannulation (ascending aorta and right atrium or com-
mon femoral vein) in 49 (24%) patients.
The ECMO circuit and cannulation protocols have been
described in detail previously.3,4 In brief, the circuit is based on a
centrifugal blood pump (Bio-Pump BP-80; Medtronic Bio-
Medicus, Eden Prairie, Minn) in conjunction with an oxygenator
(Maxima Plus PRF, Medtronic Cardiac Surgery; Medtronic, Inc,
Anaheim, Calif). All components are heparin coated. The patient is
heparinized as early as possible to attain an activated clotting time
of 180 to 250 seconds.
All patients were supported with the intention to wean from
ECMO. Intravenous inotropic doses were reduced but continued at
a lower level to maintain ventricular ejection. IABP support was
encouraged while patients received ECMO. Atrial septostomy or
ventricular venting was not used. Recovery was assessed daily by
means of clinical, hemodynamic, and echocardiographic findings.
When recovery was unlikely or uncertain, transplant screening was
initiated. Candidacy for transplantation and LVAD bridge was
made on a case-by-case basis. The only absolute contraindication
was profound neurologic injury, which was usually corroborated
by computed tomographic scan, and severe active infection. Mild-
to-moderate encephalopathy, elevated bilirubin and creatinine lev-
els, and treated intravenous line and pulmonary infections did not
exclude a patient from bridge-to-transplant consideration. In
patients with absolute contraindications to transplantation, wean-
ing was performed with the intent for survival. ECMO was with-
drawn from some patients with the knowledge that survival was
unlikely and continued support was futile.
Follow-up
Because the focus of this study was on time-related survival, all
patients were followed up as of March 2000. At that time, the range
of follow-up time among the 51 patients still alive was 1.1 to 7.5
years (mean, 3.8 ± 1.62 years). Among the 151 patients who died,
median survival was 5 days, and 142 (94%) of the 151 deaths were
within the first 6 months.
Methods of Data Analysis
Descriptive. Descriptive statistics are summarized as means
and SDs for continuous variables when they were approximately
normally distributed but as medians, 25th and 75th percentiles, and
ranges when they were not. Categorical variables are expressed as
percentages.
Analytic strategy. The primary end point for this study was
death at any time after the start of ECMO. Secondarily, we exam-
ined time-related survival after weaning from ECMO with the
intent for survival (n = 71) or bridge to transplantation (n = 48).
This secondary aim required that we also identify the predictors of
bridging, weaning, or withdrawal of ECMO life support.
Nonparametric estimates of survival were obtained by follow-
ing the method of Kaplan and Meier.5 A parametric method was
used to resolve the number of phases of instantaneous risk of death
(hazard function) and to estimate their shaping parameters.6* For
the primary end point of survival, time zero was taken as the start
of ECMO. For the secondary analysis of survival after bridging or
weaning, time zero was taken as the time the patient was removed
from ECMO.
Multivariable analyses. For the primary multivariable analysis
of time-related survival, the question being answered was as fol-
lows: What are the factors associated with time-related survival
that are known at the time of decision making for ECMO? Thus,
the variables entered into the analysis included demography, car-
diopulmonary comorbidity, noncardiac comorbidity, the type of
cardiac procedure that may have preceded ECMO, and indications
for ECMO (Appendix 1).
*Available by anonymous ftp from ftp:\\uabcvsr.cvsr.uab.edu.
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For the secondary analyses of survival after bridging or wean-
ing, the question being answered was as follows: What are the pre-
ECMO factors associated with survival, and what additional con-
tribution did events during ECMO make? Thus, a sequential
analysis was performed, first with pre-ECMO variables as delin-
eated above and then with variables related to events occurring
during ECMO and maximal recorded values for measurements
made during ECMO (Tables 1 to 3).
Initial screening of variables possibly related to survival used
the log-rank test and the Cox proportional hazards model.
Continuous and ordinal variables were assessed univariably by
means of decile analysis to suggest transformations of scale to
incorporate into the multivariable analysis to ensure that the rela-
tion of these variables to outcome was well calibrated with respect
to model assumptions. For each of the hazard models, the analysis
was performed simultaneously for each hazard phase. Variables
were identified by a guided technique of entry of variables into the
multivariable models.7
The P value criterion for retention of variables in the final
model was .1. This liberal criterion was chosen because of the
possibility that important variables related to survival would be
overlooked by too stringent a variable retention criterion as a
result of the relatively small number of deaths (type II error).
However, this strategy exposed us to the risk of model overde-
termination, whereby risk factors cease to be general common
denominators and become identifiers of specific individuals in
the data set who have died (type I error). Therefore, the low fre-
quency of occurrence variables was not used to balance these
errors, and all analyses were supplemented with bootstrap
resampling variable selection.8,9 For this, observations were
sampled at random (with replacement) from the data set to gen-
erate a new data set 75% the size of the original. This process
was repeated 1000 times. An automated stepwise variable selec-
tion was performed (retention criterion, P = .1) for each boot-
strap data set. For clusters of highly correlated variables, such as
transformations of the same or similar variables (age and body
size), only one member of each cluster was entered. By means
of this tactic, the frequency of occurrence of variables within
each category yielded an accurate assessment of the likelihood
that one member of that cluster should belong in the final model,
and it identified which transformation was the most likely one.
Thus, the risk factors identified were not only statistically sig-
nificant but also must have occurred with the highest frequency,
as determined with bootstrap analysis.10
The final strategy for the analysis was to identify those factors
that resulted in patients either being considered unsalvageable
(withdrawn, n = 83), bridged (n = 48), or weaned with intent for
survival (n = 71). These were considered competing risks.
Therefore, multivariable logistic regression analysis was used with
the variables and strategies as stated above but with pairwise con-
ditional groupings of patients, such that in the final analysis the
probability of an individual patient belonging to each of the 3
groups added to 100%.11 For these analyses, we sequentially used
factors known before ECMO and again after the addition of the
factors concerning the complications of and the process of ECMO.
Presentation. Because only 12 (6%) patients have been fol-
lowed up beyond 5 years, presentation of time-related survival has
been truncated at 5 years.
Nonparametric Kaplan-Meier time-related estimates are ac-
companied by asymmetric confidence limits equivalent to 1 SE.12
Parametric estimates are accompanied by confidence limits equiv-
alent to 1 SE.12
Tables of risk factors identified in the hazard domain are pre-
sented with their regression coefficients rather than hazard ratio
because the model is one of nonproportional hazards. Instead,
because the hazard function multivariable analyses are completely
parametric (generating an equation), nomograms from the analyses
are presented in which specific variables, such as age and creati-
nine level, are entered into the equations, the equations are solved,
and the results are presented graphically with confidence limits.
This same strategy was used in the logistic regression domain.
All confidence limits presented in this article are equivalent to
1 SE (68%) for consistency with the presentation of mean values
to 1 SD.
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TABLE 1. Complications during ECMO
Complication No. %
Infections 99 49
Dialysis 81 40
Neurologic events 66 33
Pump thrombus 12 6
Limb complications 51 25
Ischemia* 37 18
Fasciotomy 4 2
Vascular repair 6 3
Amputation 4 2
*Medically treated.
TABLE 2. Highest values during ECMO support
Percentile
Variable n Minimum 25 50 75 Maximum
BUN (mg/dL) 170 9 25 40 59 167
Creatinine (mg/dL) 173 0.6 1.5 2.2 3.3 6.5
AST (U/L) 170 1 92 204 475 21,000
Total bilirubin 179 0.3 1.7 3.1 8.9 103
(mg/dL)
BUN, Blood urea nitrogen; AST, aspartate aminotransferase.
TABLE 3. Neurologic complications during ECMO support
Weaned (n = 71) Bridged (n = 48) Withdrawn (n = 83)
Event n % n % n %
Encephalopathy 14 20 10 21 23 28
Intracranial bleeding 4 6 1 2 8 10
Stroke 2 3 1 2 3 4
Total 20 28 12 25 34 41
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Results
Survival
Survival at 24, 48, and 72 hours after initiation of ECMO
was 90%, 83%, and 76%, respectively. By 1 week, 2 weeks,
and 30 days, survival had fallen to 58%, 45%, and 38%. By
90 days, 1 year, 3 years, and 5 years, survival was 33%, 29%,
26%, and 24%. Patients surviving at 30 days had a 63% 5-
year survival. The instantaneous risk of death had 2 distinct
phases: an early high initial rate of death fell to merge at
about 1 year with a slowly declining hazard rate (Figure 1).
Pre-ECMO risk factors for death are shown in Table 4.
They included older age, with an evident difference in sur-
vival above approximately age 55 years (Figure 2). Shorter
height was a risk factor that was stronger than female sex.
Four patients had prior operations on the thoracic aorta, and
all died within 4 days of the start of ECMO. Patients who
had a history of an open-chest operation before the present
hospitalization leading to ECMO support were at higher
risk, as were patients in whom an IABP was not used and
patients who were experiencing decompensated heart fail-
ure or cardiogenic shock.
ECMO Complications and Values
Complications occurring while patients were receiving
ECMO included infection in 49%, requirement for dialysis
in 40%, neurologic events in 33%, and limb complications
in 25% (Table 1). The median transfused units of packed
cells was 14 (25th percentile, 8; 75th percentile, 21; mini-
mum, 0; maximum, 99).
ECMO Outcomes
Forty-eight patients were bridged to transplantation, 71
were weaned from ECMO with intent for survival, and 83
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Figure 1. Survival after commencing ECMO (time zero). Each sym-
bol represents a death positioned at the time of death on the hori-
zontal axis and by the Kaplan-Meier estimator on the vertical axis.
Periodically, vertical bars represent asymmetric confidence lim-
its equivalent to 1 SE. The numbers in parentheses are the number
of patients remaining at risk at the time interval shown. The solid
lines are parametric estimates enclosed in confidence limits
equivalent to 1 SE.
Figure 2. Risk-adjusted relation of age and 5-year survival. This is
a so-called nomogram of Table 4, in which height was set to 170
cm, creatinine level was set to 1.5 mg/dL after a primary nontho-
racic aortic operation, no preoperative decompensation was
used, and IABP was used.
TABLE 4.  Pre-ECMO risk factors for death after initiating
ECMO
Incremental risk factors for death Coefficient ± SD P value
Early hazard phase
Demographic
Older age* 0.29 ± 0.101 .004
Shorter height –0.031 ± 0.0113 .006
Cardiac comorbidity
Primary operation† –0.56 ± 0.26 .03
Procedure
Thoracic aortic operations 2.1 ± 0.63 .0007
Late hazard phase
Cardiac comorbidity
Reoperation† 1.68 ± 0.51 .001
Nonuse of IABP –0.93 ± 0.41 .02
Indication for ECMO
Decompensated heart failure- 1.18 ± 0.46 .01
shock
*[age/50]3; cubic transformation.
†The negative coefficient indicates that patients undergoing reoperation
were more likely to survive the early phase of risk, but the positive coeffi-
cient in the late hazard phase indicates they were more likely to have poor
survival. Thus, in total their death was somewhat protracted in time.
were withdrawn from ECMO because of futility. Forty-one
percent of those withdrawn from ECMO experienced a neu-
rologic event (Table 3).
Bridged patients. Patients were more likely to be consid-
ered for bridging to transplantation if they were younger
than 60 years of age and if their heart failure had severely
decompensated, leading to ECMO support (Table 5). In
addition, nondiabetic patients were more likely to be
bridged, as were patients in whom an IABP was used. When
events occurring during ECMO and measurements made
during ECMO (Tables 1-3) were added to the analysis,
lower total bilirubin levels during ECMO, the need for addi-
tional lower limb cannulation, and the absence of neurolog-
ic events were added (Table 5).
Survival after being bridged from ECMO to an LVAD 
(n = 42) or directly to transplantation (n = 6) was 85%, 67%,
54%, and 44% at 7 days, 30 days, 1 year, and 5 years,
respectively, after cessation of ECMO (Figure 3). Survival
to transplantation was 67%, with 92% of these patients alive
6 months after transplant. Of the 42 patients bridged to an
LVAD, 25 (60%) survived to transplantation. The only risk
factor for death was older age (P = .02). Patients who had
encephalopathy during ECMO experienced reduced sur-
vival after being bridged, with 1- and 5-year survivals of
14% among these 10 patients compared with 61% and 55%
among the 38 without this complication (P = .04).
Weaned patients. Patients were more likely to be weaned
if IABPs were being used (Table 6). Thus, of the 71 patients
weaned, 45 (63%) were receiving pre-ECMO IABP support
compared with 41 (49%) of the 83 withdrawn from ECMO
(P = .08). When events during ECMO and measurements
were added to the analysis, use of IABP was displaced by
Cardiopulmonary Support and Physiology Smedira et al
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TABLE 5. Factors increasing the likelihood of bridging
from ECMO
Variable Logistic 
coefficient ± SD P value
Pre-ECMO model
Demographic
Younger age* –0.24 ± 0.079 .002
Noncardiac comorbidity
Nondiabetic –1.28 ± 0.64 .05
Cardiac comorbidity
Use of IABP 1.01 ± 0.43 .02
Indication for ECMO
Decompensated heart failure-shock 1.54 ± 0.51 .003
Intercept 13.8
C statistic 0.79
Pre-ECMO and on-ECMO model
Demographic
Younger age* –0.27 ± 0.087 .002
Taller† 0.61 ± 0.26 .02
Indication for ECMO
Decompensated heart failure-shock 1.68 ± 0.57 .003
During ECMO
Lower total bilirubin‡ –0.67 ± 0.26 .01
Absence of neurologic events§ –1.36 ± 0.41 .0009
Additional lower limb cannulation 1.40 ± 0.57 .01
Intercept 16.0
C statistic 0.86
*Uniform age relation to age 60 years and then continuous age thereafter.
†[In[–In[height–100]/100]]2; normalized squared transformation.
‡In[total bilirubin]; natural logarithmic transformation.
§0 = None, 1 = encephalopathy, 2 = stroke; negative coefficient indicates
less likelihood of bridging when neurologic events occurred.
Figure 3. Survival after discontinuing ECMO (time zero) stratified
according to the outcome of ECMO: bridged or weaned. Format of
the depiction is as for Figure 1.
TABLE 6. Pre-ECMO and on-ECMO factors increasing the
likelihood of weaning from ECMO
Variable Logistic coefficient ± SD P value
Pre-ECMO factors
Use of IABP 0.57 ± 0.33 .08
Intercept –0.48
C statistic 0.57
On-ECMO factors
Infection 1.76 ± 0.42 <.0001
Lower total bilirubin* –0.57 ± 0.21 .008
Lower creatinine† 1.94 ± 0.84 .02
Surgically managed limb 1.70 ± 0.81 .03
Intercept –1.37
C statistic 0.77
*In[total bilirubin]; natural logarithmic transformation.
†[1/creatinine]; inverse transformation.
Smedira et al Cardiopulmonary Support and Physiology
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them (Table 6). These factors related to less subsystem fail-
ure and intensity of treatment of infections.
Survival after being weaned from ECMO was 72%, 52%,
43%, and 40% at 7 days, 30 days, 1 year, and 5 years,
respectively, which is similar to that of bridged patients
(Figure 3). Survival after weaning was influenced by the
pre-ECMO factors of shorter height, higher creatinine lev-
els, and higher international normalized ratio (Table 7). The
most powerful was the pre-ECMO serum creatinine level
(Figure 4).
Withdrawal from ECMO. Patients withdrawn from
ECMO for futility represent the complementary group to
bridged and weaned patients. Thus, their pre-ECMO risk
factors included shorter height and nonuse of IABP (Table
8). With the addition of factors during ECMO (Table 8),
worse renal and hepatic function and complications of
Figure 5. Risk-adjusted relation of ECMO serum creatinine levels
to the probability of withdrawal of ECMO. The depiction is as in
Figure 4, except bilirubin was set at 3.5 mg/dL, neurologic events
were set to “no,” pump head clots were set to “no,” and infection
was set to “no.”
TABLE 7. Risk factor for death after weaning from ECMO
with intent for survival
Risk factors for death Coefficient ± SD P value
Early hazard phase
Demographic
Shorter height* 11.8 ± 4.0 .003
Noncardiac comorbidity
Higher creatinine† –1.02 ± 0.28 .0003
Late hazard phase
Higher INR‡ –2.7 ± 1.25 .03
INR, International normalized ratio.
*[170/height (cm)]; inverse transformation.
†[2.5/creatinine]; inverse transformation.
‡[1/INR]2; inverse squared transformation.
Figure 4. Risk-adjusted relation of 30-day survival after being
weaned from ECMO to pre-ECMO serum creatinine levels. The
depiction is a nomogram of Table 7, in which height was set to 170
cm and international normalized ratio to 1.2.
TABLE 8. Pre-ECMO factors increasing the likelihood of
withdrawal of ECMO
Variable Logistic coefficient ± SD P value
Pre-ECMO model
Demographic
Shorter height* –0.28 ± 0.156 .07
Cardiac comorbidity
Nonuse of IABP –0.60 ± 0.30 .04
Intercept 0.33
C statistic 0.60
On-ECMO model
Demographic
Shorter height* –0.36 ± 0.177 .04
On-ECMO factors
Higher creatinine† –2.3 ± 0.83 .005
Higher bilirubin‡ 0.55 ± 0.193 .005
Neurologic events§ 0.53 ± 0.25 .04
No infection –1.70 ± 0.38 <.0001
Pump head clots 1.38 ± 0.71 .05
Intercept 1.00
C statistic 0.77
*[In [–ln[height–100]/100]]2.
†[2.5/creatinine]; inverse transformation.
‡ln [total bilirubin]; natural logarithmic transformation.
§0 = None, 1 = encephalopathy, 2 = stroke.
Negative coefficient indicates less likelihood of withdrawal.
ECMO dominated (Tables 3 and 8). Figure 5 shows the pro-
found influence of higher creatinine levels during ECMO,
and Figure 6 shows the influence of higher levels of biliru-
bin, leading to withdrawal of ECMO. Of the 12 patients in
whom pump head clots were found, two thirds were with-
drawn from ECMO compared with 39% of other patients 
(P = .06).
Modes of Death
The modes of death differed according to the outcome of
ECMO (Table 9). Both those withdrawn from ECMO and
those weaned from ECMO died most commonly of cardiac
failure, whereas this occurred in only 1 bridged patient; the
cause of death was nearly exclusively multiorgan system
failure.
Discussion
ECMO technology is simple to use, is rapidly initiated and
applicable to patients of all sizes, and can rapidly reverse
ischemia and anoxia. Questions remain as to the utility of
this type of support in adult patients and whether the numer-
ous complications previously reported are derived from the
insult leading to the need for ECMO or caused, perpetuated,
or both by the course of ECMO.
Principal Findings
Early mortality and morbidity remain very high for patients
requiring ECMO support. Older age, evidence of organ sys-
tem dysfunction either before or during the course of
ECMO support, a history of previous cardiac operations,
extensive aortic operations, neurologic events, and nonuse
of IABP support were variables predictive of death during
ECMO or after ECMO was withdrawn. If the patient sur-
vived the hospitalization, intermediate-term survival was
quite good and was sustained for over 5 years.
The predictors of bridging in part reflect our clinical
practice and an aggressive ECMO bridge approach to
patients already on the transplant list (severe heart failure
group). Bridging to transplantation successfully salvaged a
sizeable group of young patients who otherwise would have
died. Although the survival is less than that of those bridged
to transplantation without preceding ECMO support,13 it is
useful as a temporizing strategy, allowing time for organ
recovery and transplant assessment.
ECMO Morbidity and Mortality: The Event or the
Device?
The need for ECMO support occurs after profound car-
diopulmonary collapse, failure to wean successfully from
cardiopulmonary bypass, and decompensation of chronic
congestive heart failure. All these processes are associated
with either ischemic or reperfusion organ injury or alter-
ations in the inflammatory response leading to complement,
neutrophil, platelet, and cytokine activation.14 ECMO pro-
duces similar responses, and this undoubtedly compounds
the initial insult.15 The unanswered question is why this
occurs in some patients, but not in others.
Initiating ECMO before complete hemodynamic collapse
is ideal, but in most cases the insult has already occurred.
Therapies must be developed that alter the reperfusion injury,
preserving renal and hepatic function. Agents that affect the
inflammatory response in general, such as steroids, aprotinin,
and plasmapheresis, or more specific blockades, such as
leukocyte depletion or direct cytokine inhibition, will need
evaluation in the adult patients undergoing ECMO.
Heparin coating or bonding of the ECMO circuit was
used with the hope that it would reduce cellular and media-
tor activation in addition to the reduction in the anticoagula-
tion requirements. We found that the failure to use heparin
resulted in a high occurrence of thrombotic complications
Cardiopulmonary Support and Physiology Smedira et al
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Figure 6. Risk-adjusted relation of ECMO total bilirubin levels to
the probability of withdrawal of ECMO. The depiction is as in
Figure 5, except serum creatinine level was set to 2 mg/dL.
TABLE 9. Modes of death
Outcome
Weaned (n = 71) Bridged (n = 48) Withdrawn (n = 83)
Mode n* % of 34 n* % of 16 n* % of 82
Cardiac failure 16 47 1 6 40 49
Multiorgan  14 41 14 88 28 34
system failure
Neurologic 4 12 1 6 14 17
Total deaths 34 100 16 100 82 100
*Number of deaths within failure subgroups.
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during ECMO.16 Although pump thrombus was uncommon,
when it did occur, it was nearly always associated with the
patient dying. It has been suggested that microthromboem-
boli are occurring continuously during ECMO support and
contribute to organ injury and dysfunction.17 Strategies to
reduce these events must be developed. The prolonged use
of a centrifugal pump and a microporous membrane oxy-
genator may have perpetuated cell damage and an inflam-
matory response. The use of a less traumatic roller pump
and silicone membrane oxygenator, as used by the
University of Michigan group, may have reduced these
complications. However, using this system to bridge
patients to an implantable LVAD, Pagani and colleagues14
found a 44% 1-year survival, which is similar to that
observed by us.
Current anticoagulation protocols are suboptimal. Al-
though they reduce pump thrombosis, bleeding remains
excessive. Undoubtedly, this is multifactorial and includes
surgical trauma, anticoagulation, and thrombocytopenia.
The use of aminocaproic acid (Amicar) and aprotinin has
been advocated with mixed results in neonatal patients.18
These agents will need to be used cautiously, weighing the
risks of bleeding with those of thrombosis.
Another explanation for the poor early outcome is the
absence of pulsatile perfusion. Patients with an IABP were
more likely to be weaned or bridged than those without an
IABP. This may reflect the beneficial effects of afterload
reduction on myocardial recovery or improved organ func-
tion with pulsatile flow. Our findings support the recom-
mendation that all patients requiring ECMO support for car-
diac failure have concomitant IABP support.19 Whether
better left ventricular decompression with apical drainage
and pulsatility with the BVS 5000 LVAD (Abiomed,
Danvers, Mass) would improve myocardial recovery or sur-
vival is unclear. The overall postcardiotomy survival report-
ed by Guyton and colleagues20 with the BVS 5000 LVAD
was only 29%. In addition, the early experience with con-
tinuous flow pumping for the bridge to transplantation has
been similar to that of the implantable devices, which sup-
ports the concept that organ function can be maintained
without pulsatility.
Implications for Patient Care
The majority of patients supported with ECMO were young
and justified an aggressive approach. In the older patient
survival was markedly reduced, especially in association
with pre-ECMO renal or hepatic dysfunction or post-
ECMO neurologic injury. In this group ECMO cannot be
advocated, and if ECMO is initiated and rapid clinical
improvement is not seen, early termination of ECMO sup-
port is warranted.
ECMO provides hemodynamic stabilization and, in the
patient with insufficient myocardial recovery, time to assess
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the patient for transplantation. We aggressively bridged
patients from ECMO to an implantable LVAD, with 60% of
the patients surviving to transplantation. The only con-
traindications for this bridge-to-bridge therapy were severe
neurologic injury and active untreated infection. The
absence of predictors of survival in this subgroup suggests
that some patients with significant alteration in organ func-
tion can survive through the double bridge, albeit with a
lower survival than in a group of patients with LVADs who
are not supported with ECMO.
A substantial number of patients dying during ECMO or
after weaning from ECMO died from irreversible myocar-
dial injury. Golding and colleagues21 found that 69% of
patients autopsied after postcardiotomy ventricular support
had extensive myocardial injury. In the group of patients
who are not transplant candidates and who do not have end-
organ injury but do have insufficient myocardial recovery,
a permanent implantable cardiac assist device would sal-
vage these patients. The ongoing Randomized Evaluation of
Mechanical Assistance for the Treatment of Congestive
Heart Failure trial will help answer whether the current gen-
eration of devices are a durable and cost-effective alterna-
tive in this situation.22
Limitations
The analysis of a single clinical experience and the man-
agement protocols were evolving over the time period stud-
ied. However, results did not change substantially over time
and concur with the published results of adult patients
receiving ECMO.
Conclusions
ECMO is versatile and can salvage patients who would oth-
erwise die. Improvement in outcome will require a multi-
disciplinary approach to protect organ function and limit
organ injury that results before and during ECMO support.
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Appendix 1
Variables Considered in Multivariable Analyses
• Demographic: age (in years), height (in centimeters), weight (in
kilograms), body mass index, body surface area, sex
• Cardiopulmonary comorbidity: reoperation, preoperative use of
IABP, duration of ventilation support
• Noncardiopulmonary comorbidity: diabetes mellitus, history of
peripheral vascular disease, history of chronic obstructive pul-
monary disease, dialysis, blood urea nitrogen (in milligrams
per deciliter), serum creatinine (in milligrams per deciliter),
aspartate aminotransferase (in units per liter), total bilirubin (in
milligrams per deciliter), international normalized ratio (in
units), infection
• Preceding operations: coronary artery bypass graft, valve, coro-
nary artery bypass graft and valve, thoracic aortic aneurysm,
congenital, lung transplant, heart transplant, left ventriculec-
tomy
• Indications for ECMO: cardiac failure, postcardiotomy, post-
cardiac catheterization, acute myocardial infarction, acute res-
piratory disorder, cardiac arrest, myocarditis, postcardiac trans-
plant, after lung transplant, decompensated heart failure, post-
partum cardiomyopathy, after left ventriculectomy
• Cardiomyopathy variables: dilated cardiomyopathy, ischemic
cardiomyopathy
• ECMO details: peripheral cannula used, central cannula used,
duration of ECMO, oxygenator count, number of blood trans-
fusions during ECMO, years from January 1, 1992, to ECMO
• ECMO complications: head clot in pump count, additional
lower limb cannulation, medically managed limb complication,
surgically managed limb complication, dialysis, intracranial
bleeding, embolic stroke, encephalopathy, infection
• Highest values during ECMO: blood urea nitrogen (in mil-
ligrams per deciliter), serum creatinine (in milligrams per
deciliter), aspartate aminotransferase (in units per liter), total
bilirubin (in milligrams per deciliter), infection, international
normalized ratio (in units)
Discussion
Dr Robert H. Bartlett (Ann Arbor, Mich). There is a huge
amount of data in this article, and it takes hours or days to analyze
it, even with the article in hand. I am going to comment on a few
of the factors that were raised in this fascinating review.
First, the statistical analysis is superbly done. It is very well
described in the article. A tremendous diversity of cardiac and res-
piratory patients are mixed together in this analysis. What the
authors learned, of course, is that older patients (and the oldest was
84 years) and sicker patients with more organ failure tend to die.
Well, I guess we all knew that, but it is nice to see it confirmed. You
mentioned that older was worse, but you did not tell us what age is
“older.” Maybe you might comment on that. The subgroup analy-
sis is the really interesting part. A total of 198 patients had partial
ventricular assist bypass, almost all of which was femoral-femoral
bypass, for cardiac failure, half of which occurred postoperatively
and half during cardiogenic shock for some reason; 34% of those
patients survived. One aspect of this article is that death or survival
is defined in time increments, and we do not really know when
hospital discharge occurred. Therefore, I am assuming they proba-
bly were discharged from the hospital if they survived somewhere
between 30 and 90 days. Two thirds of the surviving patients
(either bridged to spontaneous cardiac recovery or to transplanta-
tion) lived for 5 years. This is a very good outcome for those
patients, and it begins to define the outcome of the algorithm.
About half of the 198 patients receiving ventricular assist bypass
were withdrawn from support because they were not candidates for
an LVAD or they were not candidates for transplant. However, that
is not bad; that is the algorithm. You do the best you can, you get
them on bypass, and then you sort things out.
Therefore, with that algorithm, those patients receiving ECMO
who have good brain function and reasonable organ function and
are transplant candidates go on to LVAD. Their survival was
remarkably good: 85% in this particular group. Our experience is
the same.
Thirty-one patients had respiratory failure, and 10 survived. 
I would advise the authors to write up the respiratory patients sep-
arately.
The authors raised the following question: To what extent do
the technology and the devices contribute to the mortality? It is a
very good question and something we all have to worry about.
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Their technique included the use of a centrifugal pump, which
is great for 2 hours of bypass but (in our experience) causes unac-
ceptable amounts of hemolysis and pump thrombus when used for
a long time. They used a microporous membrane oxygenator,
which undoubtedly leaked plasma and probably had to be changed
from time to time. The average activated clotting time was about
200 seconds, and we would usually use much lower than that.
Thus, there are issues in the technology that could be changed to
improve results even more.
These cases are always emergencies. Maybe you cannot stop
bypass in the operating room, or worse yet, it is the middle of the
night and your postoperative patient’s condition is suddenly dete-
riorating, or a new patient with a myocardial infarction is admitted
with profound cardiogenic shock. My question is, how do you do
it? How long does it take you to mobilize the team and get the
patient on bypass?
My second question is this: What would you consider to be the
contraindications? What patients would you not put on ECMO if
you cannot come off bypass in the operating room or have a patient
in cardiogenic shock?
Dr Moazami. Dr Bartlett, thank you very much for your com-
ments. We are certainly all aware of your excellent contributions
over the years to this technology. I will address your questions.
In terms of “older” patients not doing well, our analysis shows
that the inflection point is around 60 years, with patients older than
60 years really not doing well with this technology. I think one of
the factors that we tried to highlight in the article, and that I am
also trying to emphasize here, is that it is true that the ECMO com-
plications and ECMO factors affect survival, but pre-ECMO fac-
tors—in other words, the overall condition of a patient before
ECMO is instituted—are also contributing factors. Thus, a patient
who has baseline renal insufficiency at the time of insult or hepat-
ic insufficiency actually does not do well with ECMO. If we add
these together, I would say a patient who is 65 years old and has a
creatinine level of 2 mg/dL and a low bilirubin level of 2 to 3
mg/dL probably has about an 80% mortality on ECMO.
Your second question referred to how long it takes for us to actu-
ally implement the ECMO system. Obviously, we all recognize that
the sooner we can resuscitate the patients and put them on ECMO
for circulatory support, the better the patients will do. We, as is the
case in many other centers, have a mobile system that can be imple-
mented rapidly. The nurses are also very familiar with the manage-
ment of the system. Although I do not have exact numbers to give
you, once it is recognized that ECMO or some other form of sup-
port is necessary, the majority of these patients are taken down to
the intensive care unit, where support is initiated within 1 hour.
As you mentioned, our approach in 80% of these patients was
peripheral cannulation, which is relatively easy. When we put
patients on venovenous bypass for respiratory support, we usually
use a percutaneous method based on the Seldinger technique. In
patients in whom we use venoarterial support, we primarily do a
cutdown in the groin and place the cannulas under direct vision.
That also includes placement of a distal perfusion cannula into the
superficial femoral artery, which is now a routine practice and has
actually cut down significantly on the limb ischemia complications
APPENDIX TABLE B. Patient characteristics before ECMO
placement
Percentile
Patient characteristic Mean 
and general indication n ± SD Minimum 25 50 75 Maximum
Demographic
Age (y) 202 55 ± 14 18 47 57 65 82
Height (cm) 200 171 ± 9.4 142 165 171 178 196
Weight (kg) 200 81 ± 18 42 69 78 90 159
Noncardiac comorbidity
BUN (mg/dL) 196 28 ± 20 5 15 22 33 129
Serum creatinine 196 — 0.3 1.0 1.4 1.8 11.6
(mg/dL)
Serum AST (U/L) 168 — 1.4 23 56 181 20,300
Total bilirubin 156 — 0.05 0.8 1.1 1.8 26.7
(mg/dL)
INR (units) 140 1.4 ± 0.65 0.9 1.0 1.2 1.5 5
BUN, Blood urea nitrogen; AST, aspartate aminotransferase; INR, interna-
tional normalized ratio.
APPENDIX TABLE C. Indications for ECMO
Indication No. %
Postcardiotomy 107 53
Acute MI 33 16
ARDS 1 0.5
Decompensated heart failure 28 14
Cardiac arrest 12 6
After cardiac transplantation 7 3.5
After lung transplantation 2 1
After cardiac catheterization 7 3.5
Myocarditis 3 1.5
Postpartum cardiomyopathy 1 0.5
After left ventriculectomy 1 0.5
MI, Myocardial infarction; ARDS, acute respiratory distress syndrome.
APPENDIX TABLE A. Patient characteristics before ECMO
placement
Patient characteristic No. %
Demographic
Men 145 72
Cardiac comorbidity
Pre-ECMO use of IABP 115 57
Reoperation 79 39
Noncardiac comorbidity
Diabetes 42 21
Peripheral vascular disease 30 15
COPD 36 18
Chronic dialysis 7 3.5
Infection 33 16
COPD, Chronic obstructive pulmonary disease.
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that we used to see, particularly those that require a surgical inter-
vention in terms of fasciotomy, revascularization, or even amputa-
tion.
In terms of contraindications to ECMO support in the postcar-
diotomy patients, it is a difficult question, as many of the surgeons
who have been faced with this problem would know. If you are in
the operating room and you cannot get the patient off bypass, it is
difficult to give up. We generally have a graded response to this
sequence, which includes maximizing pharmacologic support by
addition of inotropic agents (epinephrine and milrinone). Our next
step usually is an IABP. Finally, if we cannot get the patient off
bypass, then we go to ECMO support.
Dr James Magovern (Pittsburgh, Pa). I just have a couple of
brief questions. We also have experience using ECMO for cardiac
support. In our experience patients who have a lot of bleeding and
require extensive blood transfusion often have multisystem organ
failure. Have you seen a relationship between the need for transfu-
sion and subsequent outcome of the patient?
The second issue that we have seen is that patients who recover
generally do so within 2 days. The decision, and it becomes an impor-
tant one, is how long to keep the patient on ECMO. The mean dura-
tion of support for survivors in our 10-year experience has been about
44 hours. Therefore, it makes little sense to continue the support past
3 or 4 days if the patient has not recovered function by then. My sec-
ond question is this: What is the time period under which you see
recovery, and when would you give up and stop the ECMO?
Dr Moazami. Dr Magovern, we also see a significant amount
of bleeding complications from ECMO support, to which you have
alluded. In our patient group there was a large range of blood trans-
fusions, anywhere from 1 to 99 units, but overall, our median trans-
fusion was 13 units per patient. We did not identify transfusion as
a risk factor for development of multisystem organ failure. I am
aware that this is certainly a key factor, specifically in patients who
are receiving assistance from support devices.
In terms of how long we keep the patients on ECMO, our pro-
tocol generally is to evaluate the patients within 24 hours to see
whether they can be weaned from support. At the same time, we
also initiate evaluation for whether the patient is a transplant can-
didate. During this 24 hours, as I mentioned, we optimize pharma-
cologic support and subsequently assess whether the patient can be
weaned from support by using a combination of clinical parame-
ters; looking at the pulmonary artery pressures, the cardiac output,
and the mixed venous saturations; and using transesophageal
echocardiography.
Our median duration of support for the cardiac failure group
was 21⁄2 days, which is very close to what you are suggesting, and
usually, at that point, we have a clear idea whether we can bridge
the patient to an LVAD as a more long-term form of support,
whether the patient can be weaned from support, or whether we
should withdraw support.
Dr Shyam K. Kolvekar (London, England). We have exten-
sive experience in ECMO, and I just wanted to know who manages
your ECMO in the intensive care unit. The second question main-
ly concerns your bleeding problem in transfusion and whether you
have bleeding from your operative wounds or the cannulations.
Dr Moazami. The initial management of the ECMO system is
by the physicians and perfusionists; however, the day-to-day and
hour-to-hour management is done by our intensive care unit nurs-
es, who have been trained in the management of ECMO and can
recognize problems that may arise and notify the appropriate per-
sonnel. We usually have a perfusionist in house who can respond
quickly, and obviously, the physicians are available. 
In terms of your second question, we notice bleeding from the
cannulation site, and in some cases in which we have placed the
cannulas in the operating room, bleeding can obviously come from
the mediastinum. There have been occasions in which we had to
pack the chest open and re-explore later.
Dr Marko I. Turina (Zurich, Switzerland). You are surely
aware that ECMO is rapidly being developed as a very efficient
method for postoperative support in newborns and patients with
congenital heart disease after complex reconstructions with
results that are definitely better than those seen in adults. Do you
have any idea whether it is the disease or the system and why it
works better in newborns and in children for postoperative sup-
port?
Also, do you routinely decompress the left ventricle in these
cases?
Dr Moazami. In response to your first question, I think the
indications for placement of neonatal patients on ECMO are quite
different from what we see in the adult population; generally, most
of them are receiving respiratory support, and the most excellent
results have been reported in that subgroup of patients.
In terms of your second question, whether we use any kind of
left ventricular decompression, we do not employ such decom-
pression. It is a recognized fact that ECMO support can increase
the afterload. I believe that the Michigan group, in some instances
when they think there is increased afterload, performs an atrial sep-
tostomy. In some cases apical ventriculectomies have been report-
ed, but we do not use those techniques. However, we do, as I men-
tioned earlier, keep the patients on inotropic support and maintain
ventricular ejection during this period. Part of the reason is because
of the issue with ventricular distention, but part of it is also because
we are always worried about stasis in the left ventricle and forma-
tion of intraventricular thrombosis.
